Nazli Eda Kaleli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nazli Eda Kaleli has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Murat Karadag
Izmir Biomedicine and Genome Center, İzmir, Turkey; Izmir Biomedicine and Genome Institute, Dokuz Eylul University, İzmir, Turkey
2 shared publications- Merve Arslan
Izmir Biomedicine and Genome Center, Dokuz Eylül University Health Campus, Balçova, Izmir 35330, Turkey; Izmir Biomedicine and Genome Institute, Dokuz Eylül University Health Campus, Balçova, Izmir 35330, Turkey
1 shared publication Sibel Kalyoncu
Izmir Biomedicine and Genome Center, Izmir, Turkey
1 shared publication- Sibel Kalyoncu
Izmir Biyotıp ve Genom Merkezi
1 shared publication
Latest Publications
- 1 January 2020
- Published by Elsevier
- Vol. 121, 85-114
Physicochemical determinants of antibody-protein interactions
- 1 January 2020
- Published by Elsevier
- Vol. 121, 85-114
Physicochemical determinants of antibody-protein interactions
- 18 March 2019
- Published by Wiley in Proteins: Structure, Function, and Bioinformatics
- Vol. 87 (7) , 607-618
Phage display derived therapeutic antibodies have enriched aliphatic content: Insights for developability issues
Phage display is one of the most widely used technology for antibody discovery and engineering. Number of therapeutic antibodies derived from phage display increases rapidly due to its ease of use and ability to control antibody sequence information. Although there are numerous antibody candidates as promising therapeutics, most of them fail at later stages of development due to undesired biophysical properties. Antibody candidates with poor properties should be prevented or improved in early development phases to minimize enormous loss of time and resources. In this study, we showed that phage display derived therapeutic antibodies show higher self‐interaction and polyspecificity compared to non‐phage display derived ones. To identify molecular determinants behind this, physicochemical properties of CDR regions of 137 therapeutic antibodies were analyzed. We found multiple significant differences in both heavy and light chain CDR regions. Most profoundly, aliphatic content of HCDR3, HCDR2, and LCDR3 regions were enriched in phage display derived antibodies compared to non‐phage display derived ones. Physicochemical determinants documented here seem to play important roles in polyspecific and aggregation‐prone natures of antibodies which should be avoided in early development phases.
- 18 March 2019
- Published by Wiley in Proteins: Structure, Function, and Bioinformatics
- Vol. 87 (7) , 607-618
Phage display derived therapeutic antibodies have enriched aliphatic content: Insights for developability issues
Phage display is one of the most widely used technology for antibody discovery and engineering. Number of therapeutic antibodies derived from phage display increases rapidly due to its ease of use and ability to control antibody sequence information. Although there are numerous antibody candidates as promising therapeutics, most of them fail at later stages of development due to undesired biophysical properties. Antibody candidates with poor properties should be prevented or improved in early development phases to minimize enormous loss of time and resources. In this study, we showed that phage display derived therapeutic antibodies show higher self‐interaction and polyspecificity compared to non‐phage display derived ones. To identify molecular determinants behind this, physicochemical properties of CDR regions of 137 therapeutic antibodies were analyzed. We found multiple significant differences in both heavy and light chain CDR regions. Most profoundly, aliphatic content of HCDR3, HCDR2, and LCDR3 regions were enriched in phage display derived antibodies compared to non‐phage display derived ones. Physicochemical determinants documented here seem to play important roles in polyspecific and aggregation‐prone natures of antibodies which should be avoided in early development phases.